Stock TNDM TANDEM DIABETES CARE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
48.85 USD -1.45% Intraday chart for Tandem Diabetes Care, Inc. -4.65% +65.15%
Jun. 06 Transcript : Tandem Diabetes Care, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 08:00 AM
Jun. 03 Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing MT

Evolution of the average Target Price on Tandem Diabetes Care, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8763c8511d13ea8816064.tBM2gTjdSsVbwu9E0VjGSXXFZGnW2nj9kAMXd-cYVdo.0GVE7F6uJbIElpUQlS6tZCCdO1uGoz-QwHZYRolQZIPMVgXja-gzqyyEiA~4a38c3f402e90cf717af317218790027

Analyst Recommendations on Tandem Diabetes Care, Inc.

Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing MT
Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target MT
Lake Street Adjusts Price Target on Tandem Diabetes Care to $75 From $60, Maintains Buy Rating MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $55 From $45, Maintains Buy Rating MT
Citi Upgrades Tandem Diabetes Care to Buy, Price Target at $57 MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline MT
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45 MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45 MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24 MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45 MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
48.85 USD
Average target price
49.2 USD
Spread / Average Target
+0.72%
High Price Target
75 USD
Spread / Highest target
+53.53%
Low Price Target
18 USD
Spread / Lowest Target
-63.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tandem Diabetes Care, Inc.

Redburn Atlantic
Lake Street
Stifel Nicolaus
Citigroup
UBS
Wells Fargo Securities
Leerink Partners
TD Cowen
BofA Securities
Jefferies & Co.
Baird
Barclays
Craig-Hallum
Raymond James
Cowen
Piper Sandler
Wolfe Research
Oppenheimer
SVB Leerink
Berenberg Bank

Ratings for Tandem Diabetes Care, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TNDM Stock
  4. Consensus Tandem Diabetes Care, Inc.